Review



amg900  (Amgen)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Amgen amg900
    Investigational drugs in well differentiated and dedifferentiated liposarcoma.
    Amg900, supplied by Amgen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/amg900/amg900/pmc09479065-18-0-1
    Average 90 stars, based on 1 article reviews
    amg900 - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "Beyond targeting amplified MDM2 and CDK4 in well differentiated and dedifferentiated liposarcomas: From promise and clinical applications towards identification of progression drivers"

    Article Title: Beyond targeting amplified MDM2 and CDK4 in well differentiated and dedifferentiated liposarcomas: From promise and clinical applications towards identification of progression drivers

    Journal: Frontiers in Oncology

    doi: 10.3389/fonc.2022.965261

    Investigational drugs in well differentiated and dedifferentiated liposarcoma.
    Figure Legend Snippet: Investigational drugs in well differentiated and dedifferentiated liposarcoma.

    Techniques Used: Binding Assay

    Related Articles

    other:


    Inhibition:

    Article Title: Aurora kinase inhibition: a new light in the sky?
    Article Snippet: .. In order to differentiate AMG900 from other small molecule Aurora kinase inhibitors and to definitively test the clinical benefit and mechanism-based toxicity of Aurora kinase inhibition, the Amgen team set out to maintain the selectivity of leads 1 and 2 (Figure 1) as well as their potency in MDRoverexpressing cell lines in order to maximize the potential for translation into cell-based assays and to minimize the potential for clinical resistance through transporter-mediated efflux. ..

    Drug discovery:

    Article Title: Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for Cancer
    Article Snippet: 24 , AMG900 , A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG900 in Adult Subjects With Acute Myeloid Leukemia , Leukemia , 1 , Amgen (Thousand Oaks, CA, USA) , The study reported manageable hematologic toxicities but the patient response was modest. Dose escalation was hampered due to prolonged cytopenias. , [ ]/ NCT01380756 . .. 25 , AMG900 , A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG900 in Adult Subjects With Advanced Solid Tumors , Solid tumors , 1 , Amgen , AMG900 showed acceptable tolerance. , [ ]/ NCT00858377 . .. 26 , CYC116 , A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors , Solid tumors , 1 , Cyclacel Pharmaceuticals, Inc.(Berkeley Heights, NJ, USA) , The study was terminated by the sponsors , NCT00560716.

    Article Title: Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for Cancer
    Article Snippet: .. 24 , AMG900 , A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG900 in Adult Subjects With Acute Myeloid Leukemia , Leukemia , 1 , Amgen (Thousand Oaks, CA, USA) , The study reported manageable hematologic toxicities but the patient response was modest. Dose escalation was hampered due to prolonged cytopenias. , [ ]/ NCT01380756 . .. 25 , AMG900 , A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG900 in Adult Subjects With Advanced Solid Tumors , Solid tumors , 1 , Amgen , AMG900 showed acceptable tolerance. , [ ]/ NCT00858377 .

    Article Title: Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for Cancer
    Article Snippet: .. [106]/ NCT01380756 25 AMG900 A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG900 in Adult Subjects With Advanced Solid Tumors Solid tumors 1 Amgen AMG900 showed acceptable tolerance. .. [107]/ NCT00858377 26 CYC116 A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors Solid tumors 1 Cyclacel Pharmaceuticals, Inc.(Berkeley Heights, NJ, USA) The study was terminated by the sponsors NCT00560716 Molecules 2021, 26, 1981 15 of 30 Table 1.

    Article Title: Aurora Kinase B Inhibition: A Potential Therapeutic Strategy for Cancer
    Article Snippet: .. [105] 24 AMG900 A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG900 in Adult Subjects With Acute Myeloid Leukemia Leukemia 1 Amgen (Thousand Oaks, CA, USA) The study reported manageable hematologic toxicities but the patient response was modest. ..



    Similar Products

    amg900  (TargetMol)
    97
    TargetMol amg900
    RPE-NEO and RPE-MYC cells were treated with either vehicle control (0.1% DMSO) or indicated mitotic inhibitors for 24 h before immunofluorescent staining for H3Ser10P and staining for DNA with 4’,6-diamidino-2-phenylindole (DAPI). Cells positive for H3Ser10P were scored as mitotic cells and quantified when cells were treated with compounds other than AURKB inhibitors. For cells exposed to AZD1152 and <t>AMG900,</t> mitotic cells were identified based on their condensed chromosomes revealed by DAPI staining. The following mitotic inhibitors were used at minimally effective concentrations that are known to inhibit their respective targets, AZD1152 (200 nM), AMG900 (10 nM), BAY1217389 (20 nM), Centrinone (1 μM), GSK923295 (40 nM), SB743921 HCl (1.25 nM), Sovilnesib (80 nM). (A) Representative immunofluorescent images. (B) The percentage of the mitotic cells. Data are presented as mean ± SD. ****p<0.0001. (C) Histograms show the ratio of the mitotic index (MI) in RPE-MYC cells relative to RPE- NEO cells.
    Amg900, supplied by TargetMol, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/amg900/DL-Lysine/bio_rxiv__2023__11__07__565938-209-17-18
    Average 97 stars, based on 1 article reviews
    amg900 - by Bioz Stars, 2026-10
    97/100 stars
    		  Buy from Supplier
    amg900  (Amgen)
    90
    Amgen amg900
    Investigational drugs in well differentiated and dedifferentiated liposarcoma.
    Amg900, supplied by Amgen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/amg900/amg900/pmc09479065-18-0-1
    Average 90 stars, based on 1 article reviews
    amg900 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    amg900  (Selleck Chemicals)
    93
    Selleck Chemicals amg900
    Key Resource Table
    Amg900, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/amg900/AMG-900/pmc09667883-66-0-2
    Average 93 stars, based on 1 article reviews
    amg900 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    amg900  (ApexBio)
    90
    ApexBio amg900
    Key Resource Table
    Amg900, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/amg900/amg900/pmc08948234__41467_2022_29230_MOESM1_ESM-260-23-24
    Average 90 stars, based on 1 article reviews
    amg900 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    amg900  (Adooq Bioscience LLC)
    90
    Adooq Bioscience LLC amg900
    Key Resource Table
    Amg900, supplied by Adooq Bioscience LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/amg900/aurora+kinase+inhibitor+amg+900/pm33000229-38-2-3
    Average 90 stars, based on 1 article reviews
    amg900 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    amg900 (#19176)  (Cayman Chemical)
    90
    Cayman Chemical amg900 (#19176)
    Key Resource Table
    Amg900 (#19176), supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/amg900/AMG+900/bio_rxiv__2021__04__15__439990-41-8-30
    Average 90 stars, based on 1 article reviews
    amg900 (#19176) - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    RPE-NEO and RPE-MYC cells were treated with either vehicle control (0.1% DMSO) or indicated mitotic inhibitors for 24 h before immunofluorescent staining for H3Ser10P and staining for DNA with 4’,6-diamidino-2-phenylindole (DAPI). Cells positive for H3Ser10P were scored as mitotic cells and quantified when cells were treated with compounds other than AURKB inhibitors. For cells exposed to AZD1152 and AMG900, mitotic cells were identified based on their condensed chromosomes revealed by DAPI staining. The following mitotic inhibitors were used at minimally effective concentrations that are known to inhibit their respective targets, AZD1152 (200 nM), AMG900 (10 nM), BAY1217389 (20 nM), Centrinone (1 μM), GSK923295 (40 nM), SB743921 HCl (1.25 nM), Sovilnesib (80 nM). (A) Representative immunofluorescent images. (B) The percentage of the mitotic cells. Data are presented as mean ± SD. ****p<0.0001. (C) Histograms show the ratio of the mitotic index (MI) in RPE-MYC cells relative to RPE- NEO cells.

    Journal: bioRxiv

    Article Title: MYC amplifies mitotic perturbations elicited by LXY18 to enable synthetic lethality

    doi: 10.1101/2023.11.07.565938

    Figure Lengend Snippet: RPE-NEO and RPE-MYC cells were treated with either vehicle control (0.1% DMSO) or indicated mitotic inhibitors for 24 h before immunofluorescent staining for H3Ser10P and staining for DNA with 4’,6-diamidino-2-phenylindole (DAPI). Cells positive for H3Ser10P were scored as mitotic cells and quantified when cells were treated with compounds other than AURKB inhibitors. For cells exposed to AZD1152 and AMG900, mitotic cells were identified based on their condensed chromosomes revealed by DAPI staining. The following mitotic inhibitors were used at minimally effective concentrations that are known to inhibit their respective targets, AZD1152 (200 nM), AMG900 (10 nM), BAY1217389 (20 nM), Centrinone (1 μM), GSK923295 (40 nM), SB743921 HCl (1.25 nM), Sovilnesib (80 nM). (A) Representative immunofluorescent images. (B) The percentage of the mitotic cells. Data are presented as mean ± SD. ****p<0.0001. (C) Histograms show the ratio of the mitotic index (MI) in RPE-MYC cells relative to RPE- NEO cells.

    Article Snippet: Other antimitotic agents were obtained from the following commercial sources, AZD1152 (Selleck, CAS: 722544-51-6, Cat. No. S1147), AMG900 (TargetMol, CAS: 945595-80-2, Cat. No. T6380), BAY1217389 (Selleck, CAS: 1554458-53-5, Cat. No. S8215), Centrinone (TargetMol, CAS: 1798871-30-3,Cat.

    Techniques: Staining

    Investigational drugs in well differentiated and dedifferentiated liposarcoma.

    Journal: Frontiers in Oncology

    Article Title: Beyond targeting amplified MDM2 and CDK4 in well differentiated and dedifferentiated liposarcomas: From promise and clinical applications towards identification of progression drivers

    doi: 10.3389/fonc.2022.965261

    Figure Lengend Snippet: Investigational drugs in well differentiated and dedifferentiated liposarcoma.

    Article Snippet: AMG900 (Amgen) , AURKA/B , Phase I in advanced solid tumors and AML , ( ) .

    Techniques: Binding Assay

    Key Resource Table

    Journal: Cancer cell

    Article Title: Poziotinib for EGFR exon 20 mutant NSCLC: clinical efficacy, resistance mechanisms and impact of insertion location on drug sensitivity

    doi: 10.1016/j.ccell.2022.06.006

    Figure Lengend Snippet: Key Resource Table

    Article Snippet: AMG900 , Selleck Chem , S2719.

    Techniques: Produced, Virus, Clinical Proteomics, Recombinant, Viability Assay, Lysis, In Vitro, In Vivo, Gene Expression, Mutagenesis, Software